Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
Generations of Impact: Ensuring New Cancer Treatments for Those to Come
View on PR Newswire here. Rye Brook, NY - March 20, 2019 – Everyone loves a little friendly competition, especially if the reward is saving lives and keeping families together. The Leukemia & Lymphoma Society (LLS), the world’s largest nonprofit dedicated to fighting blood cancer, knows all too well the devastation cancer causes for families and communities. LLS has kicked off its 30th annu...
Congress Introduces Cancer Drug Parity Act
Washington, DC (March 13, 2019) – The Leukemia & Lymphoma Society (LLS) is proud to support the Cancer Drug Parity Act, which will remove a key financial barrier that prevents some patients from accessing their prescribed cancer treatments. This bipartisan legislation was reintroduced today in the U.S. House of Representatives by Representative Brian Higgins (D-N.Y.), Representative Brett Guthrie (R-Ky.), Repre...
LLS OFFERS 30 SOLUTIONS TO DECREASE HEALTHCARE COSTS FOR PATIENTS
Rye Brook, N.Y. (Mar. 1, 2019) — As costs for cancer care skyrocket, The Leukemia & Lymphoma Society® (LLS) is putting forward 31 policy recommendations aimed at lowering the cost of cancer care for patients, while protecting access to quality care. Louis J. DeGennaro, Ph.D., LLS president and CEO, issued the following statement regarding the cost of cancer care: “The hig...
LLS Continues to Drive Progress to Cancer Cures
(Rye Brook, NY, Jan. 15 2019) – Groundbreaking advances that harness the body’s immune system to attack cancer cells are set to continue, as well as significant focus on new therapies for children with cancer. And expect the revolution to gain steam in cancer treatments moving away from toxic chemotherapy toward genetics-driven targeted therapies, the foundation of precision medicine. This according to L...
U.S. Senate Introduces Cancer Drug Parity Act
Washington, DC (December 12, 2018) – The Leukemia & Lymphoma Society (LLS) is proud to support the Cancer Drug Parity Act, which will ensure equality of insurance coverage for all cancer treatments, regardless of how these treatments are administered. This bipartisan legislation was introduced today in the U.S. Senate by Senator Tina Smith (D-Minn.), Senator Jerry Moran (R-Kan.), Senator Chris Murphy (D-Conn.) ...
Burlington Stores Raises More Than $37M For The Leukemia & Lymphoma Society
(RYE BROOK, N.Y., Dec. 4, 2018) – Burlington Stores and The Leukemia & Lymphoma Society (LLS) joined forces for the 17th consecutive year to help save lives and bring smiles to those touched by blood cancer. From September 9 through December 1, Burlington's more than 670 locations nationwide encouraged customers to donate $1 or more at checkout to support LLS's goal to create a world without blood cancer. This ...
LLS Releases Results of its Precision Medicine Trial in Deadly Leukemia at ASH
View full release here. SAN DIEGO, CA (Nov. 30, 2018) – The Leukemia & Lymphoma Society (LLS) continues to deliver on its promise to “Beat AML,” the deadliest of the blood cancers, through its groundbreaking Beat AML® Master Clinical Trial, a precision medicine approach to treating these cancer patients. The first results of this trial, to be announced Sunday and Monday at the 60th Amer...
LLS Fuels Next Generation of Cancer Research Committing $188 Million
View full multimedia release here. Rye Brook, NY (November 8, 2018) - Driving the dizzying pace of breakthroughs in blood cancer treatments, The Leukemia & Lymphoma Society (LLS) announced today $42 million for 80 blood cancer research teams around the world. This latest infusion of funding by LLS, the world’s largest nonprofit devoted to curing blood cancers, brings the organization’s current com...